Product Description
SNUG01 is a gene therapy drug with adeno-associated virus (AAV) as the carrier, using Shenji Changhua's exclusive therapeutic target SG001, in order to achieve the therapeutic effect of "one-time administration, long-term effect.SNUG01 in preclinical animal experiments, showing a significant protective effect on neurons.SNUG01 is expected to open a new field of ALS treatment, improve the situation of no cure, and bring new hope to patients and their families. (Sourced from: https://www.jialabtsinghua.com/newsinfo/6360337.html)
Mechanisms of Action: Gene Therapy
Novel Mechanism: No
Modality: Gene Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|